Valeant's Bausch + Lomb Gets FDA Clearance For VICTUS Femtosecond Laser Platform

(RTTNews) - Valeant Pharmaceuticals International Inc. (VRX, VRX.TO) announced that its wholly owned subsidiary, Bausch + Lomb has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the VICTUS Femtosecond Laser Platform for laser-assisted lens fragmentation during cataract surgery.

The fragmentation procedure, which follows a capsulotomy, uses the femtosecond laser to split the cataractous lens into sections. This is followed by phacoemulsification for cataract removal. The VICTUS platform offers a number of different lens fragmentation patterns depending on the cataract grade and user preference.